CLEVELAND, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 8th Annual New York Stem Cell Summit '13 Conference to be held Tuesday, February 19, 2013, in New York City.
As part of a panel entitled, "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies," Athersys' participation is as follows:
|Event:||8th Annual New York Stem Cell Summit '13|
Tuesday, February 19, 2013|
9:10 a.m. Eastern Standard Time|
Battery Gardens in Battery Park, New York|
Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.
The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548
CONTACT: William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
Lisa M. Wilson
Tel: (917) 543-9932
© 2015 Canjex Publishing Ltd. All rights reserved.